Patients with relapsed hodgkin lymphoma therapy chemotherapy with autologous stem cell transplantation. Medical search. Frequent questions

Multiple myeloma DLBCL Mantle Cell Lym Large B‑cell l Classical Hodgkin Diffuse ASCT Allogeneic Malignancies Blood and marrow transplantation High-dose chemotherapy with autologous Clinical Remission Transplant Peripheral T-cell lym Follicular lymphoma Malignant Combination with chemotherapy Bone marrow transpla Brentuximab vedotin Cancers Nodular Conventional chemotherapy Chimeric antigen receptor Radiation Tumor Platinum-based chemotherapy Antigen Immunotherapy Graft-versus-Underwent autologous Oncology Monotherapy Hematopoietic Cell Transplantation Versus chemotherapy in patients Tumors World Health Organ Survival Opdivo Post-transplantation Cancer Antibody-drug conjugate Lymphoid Leukemias and lymphomas Hodgkin's Lymphoma Systemic therapy Newly diagnosed Disease Nivolumab Acute Outcomes Treatment Protocols Aggressive lymphomas Leukemia Etoposide Inhibitors Rituximab Regimen Prognosis Pembrolizumab Investigational Diagnosis

Multiple myeloma (MM) patients with high-risk cytogenetic abnormalities have inferior survival outcomes and are underrepresented in clinical trials. (bvsalud.org)
Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. (smw.ch)
At this year's ASH meeting, data from the Phase 3 TOURMALINE-MM3 trial, evaluating the effect of NINLARO (ixazomib) as a maintenance therapy in adult patients diagnosed with multiple myeloma who responded to high-dose therapy (HDT) and autologous stem cell transplant (ASCT), will be presented for the first time during an oral session on Sunday, December 2 at 7:30 a.m. (covaipost.com)
The breadth and depth of Takeda's research and development will be further showcased throughout several presentations focused on multiple myeloma, lymphoma, chronic myeloid leukemia and myelodysplastic syndromes (MDS). (covaipost.com)
Autologous hematopoietic stem cell transplantation (aHSCT) is a well-established treatment for hematologic malignancies such as multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). (bloodline.net)
If you've been diagnosed with a blood cancer, such as leukemia, lymphoma or multiple myeloma, and have questions about your treatment plan, or if you're interested in a second opinion on your diagnosis, call us or chat online with a member of our team. (cancercenter.com)
B-cell maturation antigen-(BCMA) targeted CAR T-cells are approved for relapsed and/or refractory multiple myeloma . (cancercenter.com)
Updated results will also be presented from a phase 1 study of the investigational agent SEA-BCMA in patients with relapsed/refractory multiple myeloma. (businesswire.com)
Evaluating the long-term effectiveness and safety of daratumumab plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. (medivizor.com)
Decadron) (D-Vd) regimen in patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that the D-Vd regimen significantly increased the overall survival in these patients. (medivizor.com)
In this review, we aim to summarize the composition of CAR-T cell and its application in the treatment of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL), multiple myeloma (MM), and acute myeloid leukemia (AML). (hindawi.com)
The technique has also shown preliminarily promising outcomes in B cell acute lymphoblastic leukemia (B-ALL), B cell non-Hodgkin's lymphoma (B-NHL), chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma and multiple myeloma in clinical trials targeting CD19, CD20, CD22, CD30 and B-cell maturation antigen (BCMA), with many more under investigation. (bdbiosciences.com)
bb2121) demonstrated promising efficacy among patients with relapsed/refractory multiple myeloma (RRMM), according to results from a phase 2 trial presented at the ASCO20 Virtual Scientific Program. (cancertherapyadvisor.com)

Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. (medscape.com)
Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
Outcome data are in line with previously reported studies, especially the data for salvage treatment and BEAM conditioning in DLBCL patients confirmed the outcome reported recently in a phase III study. (smw.ch)
Initial lymphoma stage and number of previous treatment lines were identified as independent risk factors for EFS in DLBCL and HL patients. (smw.ch)
A recently published study showed that when patients have an early first relapse of their diffuse large B-cell lymphoma (DLBCL) patients have better outcomes," says Leslie Popplewell , MD, Medical Director of Hematology and Blood and Marrow Transplant at City of Hope ® Cancer Center Atlanta . (cancercenter.com)
CAR T-cell therapy has really begun to displace autologous stem cell transplants as the preferred treatment for diffuse, large B-cell lymphoma [DLBCL] in early first relapse," Dr. Popplewell says. (cancercenter.com)
The purpose of this study is to learn about the effects of two study medicines (maplirpacept [PF-07901801] and glofitamab) when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that is relapsed or is refractory. (survivornet.com)
DLBCL is a type of non-Hodgkin lymphoma (NHL). (survivornet.com)
Everyone taking part will receive the same fixed doses of glofitamab and obinutuzumab studied in patients with DLBCL. (survivornet.com)
Additional data presented in an oral presentation at ASCO (Abstract #8013) demonstrate that adding BEXXAR to BEAM (BCNU, etoposide, ara-C, and melphalan) chemotherapy as a conditioning regimen prior to autologous stem cell transplant (ASCT) in patients with relapsed or high-risk chemosensitive diffuse large B-cell lymphoma (DLBCL) resulted in 78% of the patients achieving a complete remission following the transplant. (salesandmarketingnetwork.com)
BEXXAR is also currently being tested in a Phase III trial in the Bone Marrow Transplant Clinical Trials Network (BMT/CTN) of Rituximab + BEAM vs. BEXXAR + BEAM in patients with relapsed DLBCL. (salesandmarketingnetwork.com)
Chimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. (frontiersin.org)
Blood cell and serum markers, along with clinical data of DLBCL patients who were scheduled for CART cell therapy were evaluated to search for biomarkers predicting CART cell responsiveness. (frontiersin.org)
Compared to healthy controls (n=24), DLBCL patients (n=33) showed significant lymphopenia, due to low CD3 + CD4 + T helper and CD3 - CD56 + NK cell counts, while cytotoxic CD3 + CD8 + T cell counts were similar. (frontiersin.org)
Low frequency of differentiated CD3 + CD27 - CD28 - T cells at leukapheresis represents a novel pre-infusion blood biomarker predicting a favorable response to CART cell treatment in r/r DLBCL patients. (frontiersin.org)
Diffuse large B cell lymphoma (DLBCL) represents the most frequent form of non-Hodgkin's lymphoma (NHL). (frontiersin.org)
SummaryDiffuse large B‑cell lymphoma (DLBCL) comprises 30-40% of non-Hodgkin's lymphoma. (deepdyve.com)
Patients with resistant or relapsed (r/r) DLBCL have a poor prognosis with a median overall survival of 6,3 months and low complete response rates (CR 7%) to salvage chemoimmunotherapy. (deepdyve.com)
Several factors hinder the identification of risk factors for central nervous system (CNS) involvement in diffuse large B-cell lymphoma (DLBCL), including the retrospective nature of most studies, the relatively low frequency of CNS relapse in DLBCL, and the heterogeneity of CNS prophylaxis methods used in these studies. (haematologica.org)
Influence of systemic rituximab treatment on the incidence of CNS relapse in DLBCL and risk factors for CNS disease. (haematologica.org)
Plutarch About 30% to 40% of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) experience relapse, and 10% are refractory to the. (ascopost.com)
liso-cel) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) following 2 or more lines of systemic therapy. (onclive.com)

Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells localized in primary follicles or in the mantle region of secondary follicles. (medscape.com)
Mantle cell lymphoma (MCL) is recognized in the Revised European-American Lymphoma and World Health Organization classifications as a distinct clinicopathologic entity. (medscape.com)
Mantle cell lymphoma (MCL) is a type of non-Hodgkin B cell lymphoma with a distinctive molecular marker cyclin D1 that is constitutively overexpressed in almost all cases. (bmj.com)
Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma, which is a form of cancer that affects the lymphatic system. (rarediseases.org)
Mantle cell lymphoma belongs to a group of diseases known as non-Hodgkin's lymphomas, which are related malignancies (cancers) that affect the lymphatic system. (rarediseases.org)
The next-generation inhibitor of Bruton's tyrosine kinase (BTK) may be effective in mantle cell lymphoma for patients previously treated with an older BTK inhibitor, according to results from the phase I/II BRUIN trial. (ascopost.com)

Malignant blast cells (i.e. diffuse large B-cell lymphoma) are fast-growing and result in aggressive disease, whereas malignant mature lymphocytes (i.e. follicular lymphoma) behave indolently. (oncolink.org)
Non Hodgkin Lymphoma Clinical Trial: A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. (survivornet.com)
3 - 5 This report by the Spanish Lymphoma Group (GELTAMO) aims to provide useful guidelines and recommendations for the prevention, diagnosis, and treatment of central nervous system diffuse large B-cell lymphoma patients with, or at risk of, leptomeningeal and/or brain parenchyma lymphoma relapse. (haematologica.org)
CAR-T cells, which incorporate an antibody-derived extracellular receptor and T cell derived intracellular signaling domains, have shown convincing outcomes in certain types of leukemia and lymphoma, including commercial licensure of CD19 CAR-Ts for the treatment of relapsed/ refractory large B cell lymphoma and acute lymphoblastic leukemia. (bdbiosciences.com)
On April 1, the U.S. Food and Drug Administration (FDA) approved axicabtagene ciloleucel (Yescarta) for adult patients with large B-cell lymphoma (LBCL) who are refractory to first-line chemoimmunotherapy or who experienced relapse within 12 months of first-line chemoimmunotherapy. (ascopost.com)
As reported in The New England Journal of Medicine by Frederick L. Locke, MD, and colleagues, the phase III ZUMA-7 trial of patients with large B-cell lymphoma has shown improved event-free survival with second-line axicabtagene ciloleucel vs chemoimmunotherapy with high-dose chemotherapy and. (ascopost.com)
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of lisocabtagene maraleucel for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B following 2 or more lines of systemic therapy. (onclive.com)

The abstracts, including five oral presentations, highlight updated and interim efficacy and safety clinical trial results for ADCETRIS in both early- and advanced stage settings of classical Hodgkin lymphoma (cHL), and in patients with other CD30-expressing lymphomas and other rare cancers. (businesswire.com)
Adcetris) plus nivolumab (Opdivo) consolidation therapy after autologous hematopoietic stem-cell transplantation (HSCT) in patients with high-risk relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). (medivizor.com)
Evaluating the effectiveness and safety of penpulimab in patients with relapsed or refractory classical Hodgkin lymphoma. (medivizor.com)
In a nutshell This study evaluated the effectiveness and safety of penpulimab (AK105) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). (medivizor.com)
Some background Classical Hodgkin lymphoma (cHL) is a cancer of. (medivizor.com)
Pembrolizumab monotherapy is an established treatment strategy for relapsed or refractory classical Hodgkin lymphoma. (ascopost.com)

it was frequently categorized as diffuse small-cleaved cell lymphoma (by the International Working Formulation) or centrocytic lymphoma (by the Kiel classification). (medscape.com)
The bone marrow biopsy showed 100% cellularity with diffuse infiltration by mononucleated cells and some multinucleated forms [Figure 2] . (jahjournal.org)

Cycles are repeated every 14 days for 3 cycles, then high-dose chemotherapy with autologous stem-cell transplantation follows (if the patient is considered eligible for HDCT and ASCT). (wikipedia.org)
Treatment selection takes into account patient age, fitness, and whether autologous stem cell transplantation (ASCT) is planned. (medscape.com)
OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
METHODS: Patient charts and our prospective ASCT database were assessed for the impact of documented variables on event free survival (EFS) and overall survival (OS), including salvage and conditioning regimens used, and PET/CT results before and after ASCT. (smw.ch)
We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients. (e-crt.org)

Outcomes of myelofibrosis (MF) with allogeneic stem cell transplantation (allo-SCT) have improved over the past decade, related in part to advances in supportive treatments and conditioning regimens. (bvsalud.org)
Further relapses in 2006 and 2007 were treated with radiotherapy and chemotherapy, respectively, before the patient underwent an allogeneic peripheral stem cell transplantation in July 2008. (cdc.gov)
Even patients who are not cured with initial therapy can often be salvaged with alternate chemotherapy combinations, the novel antibody-drug conjugate brentuximab, or high-dose autologous or allogeneic hematopoietic stem cell transplantation. (johnshopkins.edu)
Alternate donor sources and reduced-intensity conditioning have made allogeneic hematopoietic stem cell transplantation a viable option for more patients. (johnshopkins.edu)
No prior autologous or allogeneic hematopoietic cell transplantation. (stanford.edu)
Solid tumors, autoimmune diseases, graft versus host disease (GvHD), genetic diseases and neurodegenerative diseases are investigated using many types of autologous and allogeneic cells with rapidly evolving cell engineering and editing approaches. (bdbiosciences.com)
The median number of prior lines of systemic therapy received was 3 (range, 1-8), 33% received prior autologous transplant, 3% had prior allogeneic transplant, and 59% received bridging therapy. (onclive.com)

In case of CD20-positive B cell lymphoid malignancies the ICE regimen is often combined today with rituximab. (wikipedia.org)
Most of these malignancies are of B-cell origin. (oncolink.org)
Chimeric antigen receptor-modified T (CAR T) cells exhibit very effective function in elimination of relapsed/refractory B-cell lymphoid malignancies, we investigated their use in a patient with relapsed MCL. (bmj.com)
Our ongoing Immuno-Oncology clinical program is looking at broad patient populations, across multiple solid tumors and hematologic malignancies, and lines of therapy and histologies, with the intent of powering our trials for overall survival and other important measures like durability of response. (bms.com)
Bristol-Myers Squibb has a broad development program in thoracic malignancies, including SCLC, non-small cell lung cancer and malignant pleural mesothelioma. (bms.com)
T cell immune protection plays a pivotal role in the treatment of patients with hematological malignancies. (hindawi.com)
However, T cell exhaustion might lead to the possibility of immune escape of hematological malignancies. (hindawi.com)
Adoptive cell therapy (ACT) with chimeric antigen receptor T (CAR-T) cells can restore the activity of exhausted T cell through reprogramming and is widely used in the treatment of relapsed/refractory (r/r) hematological malignancies. (hindawi.com)
However, CAR-T cells can also produce some adverse events after treatment of hematological malignancies, such as cytokine release syndrome (CRS), neurotoxicity, and on-target/off-tumor toxicity, which may cause systemic immune stress inflammation, destruction of the blood-brain barrier, and even normal tissue damage. (hindawi.com)
Traditionally, the treatment of hematological malignancies is administrated by chemotherapy, radiotherapy, and stem cell transplantation. (hindawi.com)
In recent years, with the increased understanding of the molecular genetic basis of these malignancies, immune-targeted therapy has become a new possibility for the treatment of hematological malignancies. (hindawi.com)
It is noted that T cell has great potential for immunotherapy of hematological malignancies. (hindawi.com)
In addition, the isolation and storage of umbilical cord blood hematopoietic stem cells have been used to rebuild the immune system for the treatment of hematological malignancies and might be promising for the dynamic equilibrium expansion of functional T cells [ 12 ]. (hindawi.com)
SummaryChimeric antigen receptor T cells (CAR-T cells) are a novel form of cellular immunotherapy for patients with hematologic and oncologic malignancies. (deepdyve.com)
Investigational cell therapies are addressing a wide range of hematological malignancies. (bdbiosciences.com)

The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
Recorded at the annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Marseille, France. (thepatientschannel.com)

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. (medscape.com)
High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)

Bristol Myers Squibb thanks the patients and investigators involved in the CheckMate -67T clinical trial. (businesswire.com)
Guideline] NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma. (medscape.com)
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (medscape.com)
Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
With the presentation of data from two Phase 3 clinical trials as well as our pipeline, Takeda continues to grow the body of evidence for new therapeutic options that improve the way in which we treat blood cancer patients," said Christophe Bianchi, M.D., President, Takeda Global Oncology Business Unit. (covaipost.com)
After many years of limited progress in the treatment of malignant mesothelioma, we saw an important clinical benefit for patients with nivolumab plus ipilimumab in the CheckMate -743 trial," said Paul Baas, M.D., Ph.D., Department of Thoracic Oncology, Netherlands Cancer Institute and the University of Leiden. (pharmiweb.com)
Bristol-Myers Squibb Company (NYSE: BMY) and PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an exclusive clinical collaboration agreement to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus' enadenotucirev, a systemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb's Immuno-Oncology (I-O) agent Opdivo (nivolumab) to treat a range of tumor types in late-stage cancer patients. (bms.com)
The clinical collaboration will support Phase 1 studies to determine whether combining these two agents can significantly improve the proportion of patients achieving objective tumor responses, the extent of tumor shrinkage, and/or the durability of responses. (bms.com)
This collaboration continues to expand our clinical development of Opdivo and explores how oncolytic viruses may provide a complementary mechanism to address tumors that are resistant to I-O therapy," said Jean Viallet, M.D., Global Clinical Research Lead, Oncology, Bristol-Myers Squibb. (bms.com)
Our differentiated clinical development program is studying broad patient populations across more than 50 types of cancers with 24 clinical-stage molecules designed to target different immune system pathways. (bms.com)
Our deep expertise and innovative clinical trial designs position us to advance the I-O/I-O, I-O/chemotherapy, I-O/targeted therapies and I-O/radiation therapies across multiple tumors and potentially deliver the next wave of therapies with a sense of urgency. (bms.com)
This regimen was found to induce durable clinical and molecular remissions in patients with this disease. (salesandmarketingnetwork.com)
Computed tomography-based tumor volume in non-Hodgkin lymphoma: clinical correlation and comparison with magnetic resonance imaging. (medscape.com)
Of note, CD19, CD20, CD30, CD33, CD123, and CD269 as ideal targets have shown extraordinary potential for CAR-T cell therapy and other targets such as CD23 and SLAMF7 have brought promising future for clinical trials. (hindawi.com)
The Breakthrough Therapy Designation is based on clinical data which were recently reported at the 2019 American Society of Clinical Oncology ( ASCO ) Annual Meeting from the cohort of patients with metastatic melanoma that were treated with the doublet therapy in the ongoing PIVOT-02 Phase 1/2 clinical study. (nektar.com)
FDA Breakthrough Therapy Designation is intended to expedite the development and review of medicines aimed at treating a serious or life-threatening disease where there is preliminary clinical evidence that the investigational therapy may offer substantial improvement over existing therapies on at least one clinically significant endpoint. (nektar.com)
A Phase 3 clinical trial evaluating bempegaldesleukin in combination with nivolumab versus nivolumab in first-line advanced melanoma patients is currently recruiting patients ( NCT03635983 ). (nektar.com)
1 In clinical and preclinical studies, treatment with bempegaldesleukin resulted in expansion of these cells and mobilization into the tumor micro-environment. (nektar.com)
The revision to the strategic collaboration agreement includes a new joint development plan under which Nektar and Bristol-Myers Squibb will expand the active clinical development program for bempeg plus nivolumab from three ongoing registrational trials in first-line metastatic melanoma, first-line cisplatin-ineligible metastatic urothelial cancer and first-line metastatic renal cell carcinoma (RCC) to include two additional registrational trials in adjuvant melanoma and in muscle-invasive bladder cancer. (pharmaceuticaldaily.com)
To date, the Opdivo clinical development program has treated more than 35,000 patients. (pharmaceuticaldaily.com)
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. (lookformedical.com)
Immuno-oncology has entered the field, and besides the checkpoint death receptor and ligand molecules PD-1/PD-L1 more molecules have been detected and are also tested in clinical studies.To provide equal opportunities to our patients the tests have to be implemented in all pathological institutes involved in lung cancer management. (deepdyve.com)
Clinical factors such as a high International Prognostic Index (IPI) or molecular factors as cell of origin (COO) have an influence on the clinical outcome after conventional immunochemotherapy. (deepdyve.com)
So let's meet Harriet Denz-Penhey PhD, Research Associate Professor, Rural Clinical School, University of Western Australia, who showed up in the comments after a post in which I commented on a brilliant video from The Onion showing what some cancer quacks in effect fool patients into doing, namely denying that they have cancer. (respectfulinsolence.com)
Building off experience in hematopoietic stem cell transplant and exploiting advances in genetic engineering, genome editing, immunology, immunotherapy, stem cell biology, understanding disease mechanisms and cell therapy manufacturing, considerable progress has been made with hundreds of clinical trials underway. (bdbiosciences.com)
T cell-targeted immunomodulators such as monoclonal antibodies against PD-1 or CTLA4 may be used in combination with CAR-T cells in clinical trials. (bdbiosciences.com)
2. Clinical epidemiology - using data from the Swedish Lymphoma Registry to provide clinically useful real world data on treatment and prognosis, in many cases in collaboration with Nordic colleagues. (lu.se)
As reported in the Journal of Clinical Oncology by Teachey et al, the phase III Children's Oncology Group AALL1231 trial has shown that the addition of bortezomib to a modified augmented Berlin-Frankfurt-Münster (BFM) backbone improved survival outcomes in patients with newly diagnosed T-cell. (ascopost.com)
CancerTherapyAdvisor.com is a free online resource that offers oncology healthcare professionals a comprehensive knowledge base of practical oncology information and clinical tools to assist in making the right decisions for their patients. (cancertherapyadvisor.com)

[ 1 ] This may result in prolonged remission, but relapse is to be expected. (medscape.com)
The patient achieved a partial remission, with minimal residual disease. (bmj.com)
With few exceptions, stem cell transplantation is usually reserved for patients with aggressive lymphomas after incomplete remission or relapse. (msdmanuals.com)
One example is a human study in which researchers discovered that higher levels of the antioxidant selenium in the blood of patients with aggressive B-cell non-Hodgkin's lymphoma correlated with increased achievable doses of anthracycline based chemotherapy, better treatment response, achievement of long term remission, and longer overall survival. (pinestreetfoundation.org)
For patients who achieved complete remission, the median time before their disease progressed was 9.2 years. (salesandmarketingnetwork.com)
Following that, patients may be eligible for a stem cell transplant, and/or an extended course of immunotherapy that is meant to prolong cancer remission. (rarediseases.org)
This association was even more pronounced when patients were stratified for complete remission (CR versus non-CR: 13.7 ± 11.7% versus 37.7 ± 17.4%, P=0.001). (frontiersin.org)
Relapse after achieving initial remission or failure to achieve initial remission. (stanford.edu)

Positive data from the TOURMALINE-MM3 trial, the first and only Phase 3 placebo-controlled study evaluating a proteasome inhibitor in this setting, showed that using NINLARO as a post-autologous stem cell transplant maintenance treatment improved progression-free survival over the control arm, highlighting NINLARO's potential use as a maintenance therapy in a patient population where there are currently limited options. (covaipost.com)
The use of autologous transplant in Hodgkin's and non-Hodgkin's lymphoma has significantly improved the survivals of patients with relapsed disease. (bloodline.net)
Treatment for Hodgkin lymphoma (HL) is tailored to each individual and may include surgery, radiation therapy, chemotherapy, precision cancer medicines and or stem cell transplant in selected situations. (hoapb.com)
Most patients with Hodgkin's Lymphoma are cured with first-line chemotherapy however, a small proportion of patients are non-responders or relapse, who have to undergo an autologous stem cell transplant. (thepatientschannel.com)
Are unable or unwilling to undergo a stem cell transplant or CAR-T cell therapy. (survivornet.com)
Stem cell transplant is a procedure in which a patient receives healthy blood-forming cells to replace their own stem cells that have been destroyed by treatment. (survivornet.com)
Time trends in risk and risk determinants of non-hodgkin lymphoma in solid organ transplant recipients. (medscape.com)
This trial uses a combination of high dose chemotherapy with stem cell transplant using the patient's own cells. (stanford.edu)
This is followed with non-myeloablative transplant using stem cells from a related or unrelated donor to try and generate an anti-lymphoma response from the new immune system. (stanford.edu)

Additionally, the positive data from the ECHELON-2 trial demonstrated that in patients with previously untreated CD30-positive peripheral T-cell lymphoma, ADCETRIS in combination with chemotherapy was superior to the control arm for progression-free survival and overall survival, representing an important milestone for ADCETRIS as a potential therapy in this setting where standard of care has not changed in several decades. (covaipost.com)

The t(14;18) translocation (characteristic for follicular lymphoma but also common in other types) results in activation of the BCL-2 gene and suppression of apoptosis. (oncolink.org)
Important types include follicular lymphoma and small lymphocytic lymphoma . (oncolink.org)
Follicular lymphoma international prognostic index. (medscape.com)

Revised response criteria for malignant lymphoma. (medscape.com)
The European Commission's approval of Opdivo plus Yervoy is a crucial step in addressing the unmet needs of patients with malignant pleural mesothelioma. (pharmiweb.com)
The nature of disease (indolent vs. aggressive) is correlated to the stage of lymphocytic differentiation of the malignant cells. (oncolink.org)
Non-Hodgkin lymphomas are a heterogeneous group of disorders involving malignant monoclonal proliferation of lymphoid cells in lymphoreticular sites, including lymph nodes, bone marrow, the spleen, the liver, and the gastrointestinal tract. (msdmanuals.com)
Лімфома Ходжкіна Hodgkin lymphoma is a localized or disseminated malignant proliferation of cells of the lymphoreticular system, primarily involving lymph node tissue, spleen, liver, and bone marrow. (msdmanuals.com)
Загальні відомості про лейкоз Leukemia is a malignant condition involving the excess production of immature or abnormal leukocytes, which eventually suppresses the production of normal blood cells and results in symptoms. (msdmanuals.com)
MCL is a B-cell lymphoma that develops from malignant B-lymphocytes within a region of the lymph node known as the mantle zone. (rarediseases.org)
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. (lookformedical.com)
Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation. (lookformedical.com)
The area of research for our group is malignant lymphomas - all possible aspects, aiming for the improvement of the quality of life and survival of these patients. (lu.se)
Plasma cell myeloma is a malignant proliferation of plasma cells in bone marrow associated with an M-protein in serum and/or urine. (jahjournal.org)

In this article, we turn our focus to lymphoma, conducting a systematic search for published research that would support or discourage the use of antioxidants in combination with chemotherapy. (pinestreetfoundation.org)
In combination with chemotherapy, the checkpoint inhibitor is also showing value in the front-line setting and further boosting outcomes in the relapsed setting, according to. (ascopost.com)

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. (smw.ch)
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. (smw.ch)
High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)

Evaluating the effectiveness and safety of brentuximab vedotin plus nivolumab consolidation therapy after autologous hematopoietic stem-cell transplantation in patients with high-risk classic Hodgkin lymphoma. (medivizor.com)

In the CheckMate -743 trial, this dual immunotherapy combination demonstrated a clinically meaningful improvement in survival over the standard of care, with 41% of patients who received Opdivo plus Yervoy still alive at two years, compared to only 27% with chemotherapy," said Abderrahim Oukessou, M.D., vice president, thoracic cancers development lead, Bristol Myers Squibb. (pharmiweb.com)
Non-Hodgkin lymphoma is not one disease but rather a category of lymphocyte cancers with a number of subgroups largely divided into aggressive and indolent types. (msdmanuals.com)
Non-Hodgkin lymphoma is the 2nd most common cancer in HIV-infected patients Неходжкінські лімфоми AIDS-defining cancers in patients infected with HIV are Kaposi sarcoma Lymphoma, Burkitt (or equivalent term) Lymphoma, immunoblastic (or equivalent term) Lymphoma, primary, of central nervous system прочитати більше , and some AIDS patients present with lymphoma. (msdmanuals.com)
Emily is one of many success stories of CAR T-cell therapy in the treatment of blood cancers. (cancercenter.com)
Through genomic-biomarker testing performed on cells from the biopsy or collected in blood doctors are increasingly able to define the genomic alterations in a cancers DNA that are driving the growth of the cancer. (hoapb.com)
Sabine Maier, M.D., development lead, thoracic cancers, Bristol-Myers Squibb, commented, "Small cell lung cancer is a highly aggressive disease in which significant unmet need remains. (bms.com)
Small cell lung cancer (SCLC) is one of two main types of lung cancer and accounts for about 10% to 15% of all lung cancers. (bms.com)
Our vision for the future of cancer care is focused on researching and developing transformational medicines, including Immuno-Oncology (I-O) therapeutic approaches, for hard-to-treat cancers that could potentially improve outcomes for these patients. (bms.com)
We've seen tremendous scientific advancements in the treatment of non-metastatic non-small cell lung cancer in recent years, and remain committed to researching new solutions that may help even more patients achieve better long-term outcomes," said Abderrahim Oukessou, M.D., vice president, thoracic cancers global program lead, Bristol Myers Squibb. (santaclara.com)
Taken together with the data from our CheckMate -816 trial - which led to Opdivo being the only anti-PD-1 with an approval in the neoadjuvant setting - today's results reinforce our leadership in resectable non-small cell lung cancer and add to our legacy of transformational science in thoracic cancers. (santaclara.com)
Lymphomas are cancers that involve white blood cells, and can be divided depending on the type of cell involved, either B-lymphocytes or T-lymphocytes. (rarediseases.org)
Even with notable progress in the treatment of metastatic renal cell carcinoma, there are still limited treatment options available for patients with localized disease," said Dana Walker, M.D., M.S.C.E., vice president, development program lead, genitourinary cancers, Bristol Myers Squibb. (wapakdailynews.com)
Opdivo and Opdivo -based combinations have shown survival benefits in several earlier-stage and advanced cancers, including genitourinary tumors, and we are disappointed that the final analysis of CheckMate -914 Part A did not show this same benefit for the post-surgical treatment of patients with localized RCC. (wapakdailynews.com)
Indeed, as I have pointed out before, this study appears almost intentionally designed to leave out the very types of cancers for which chemotherapy provides the most survival benefit. (respectfulinsolence.com)
We look forward to the European Commission's decision as we continue to accelerate our research in cell therapy to develop new treatment options for patients living with difficult-to-treat blood cancers. (onclive.com)

A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. (medscape.com)
The patient's medical history showed grade IVB nodular sclerosing Hodgkin lymphoma, which had been diagnosed in 2001. (cdc.gov)
in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. (lookformedical.com)

Case presentation Here, we report a case of a refractory MCL in a patient who had relapsed after conventional chemotherapy and autologous CAR T cell therapy. (bmj.com)

[ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
Emily Whitehead was 6 years old and near death at the Children's Hospital of Philadelphia when she became the first pediatric patient to receive yet-to-be approved chimeric antigen receptor (CAR) T-cell therapy to treat her leukemia. (cancercenter.com)
Engineered chimeric antigen receptor (CAR) T cell therapies (CAR-T) are now commercially available to treat certain leukemias and lymphomas. (bdbiosciences.com)

The Nigro protocol, by the way, consists of combined chemotherapy and radiation and is still the standard of care for anal cancer. (sciencebasedmedicine.org)
At Bristol-Myers Squibb, we have a vision for the future of cancer care that is focused on Immuno-Oncology, now considered a major treatment choice alongside surgery, radiation, chemotherapy and targeted therapies for certain types of cancer. (bms.com)
occasionally, radiation therapy is added. (msdmanuals.com)
Even in advanced-stage disease, HL is highly curable with combination chemotherapy, radiation, or combined-modality treatment. (johnshopkins.edu)
Radiation therapy uses high-powered energy beams, such as X-rays or protons, to kill cancer cells. (hoapb.com)
The objective of radiation therapy is to kill cancer cells for a maximum probability of cure with a minimum of side effects. (hoapb.com)
Radiation is usually given in the form of high-energy beams that deposit the radiation dose into the body where cancer cells are located. (hoapb.com)
Radiation therapy, unlike chemotherapy, is considered a local treatment. (hoapb.com)
Cancer cells can only be killed where the actual radiation is delivered to the body. (hoapb.com)
If cancer exists outside the radiation field, the cancer cells are not destroyed by the radiation. (hoapb.com)
Radiation therapy is an important treatment modality for patients with Hodgkin lymphoma. (hoapb.com)
However, radiation therapy is usually not the sole treatment for Hodgkin lymphoma except in selected circumstances. (hoapb.com)
Chemotherapy alone or combined modality treatment with chemotherapy and radiation therapy is typically utilized even for early stage lymphoma. (hoapb.com)
Therefore, it is essential for patients with Hodgkin lymphoma to be treated at medical centers where medical oncologists, radiation oncologists and surgeons work together. (hoapb.com)
Chemotherapy has been the standard of care in the front-line setting, with or without radiation therapy. (bms.com)
Combined, these agents form a radiolabeled monoclonal antibody regimen that is able to bind to the target antigen CD20 found on B cells, including normal B-cells and those that become cancerous in NHL, thereby delivering the dose of radiation. (salesandmarketingnetwork.com)
BEXXAR, which is given in four visits over one to two weeks, is specifically dosed based on an individual's drug clearance rate, allowing the delivery of a predetermined amount of radiation to each patient. (salesandmarketingnetwork.com)
This CME reviews the latest advances in cancer treatment options including surgical techniques, and radiation and systemic therapies. (pennmedicine.org)
Join Dr. Richard Maughn, a Penn Medicine Radiation Oncology physicist guides viewers through a behind the scenes tour of the Roberts Proton Therapy Center. (pennmedicine.org)

Intravenous Opdivo has helped transform the treatment of several solid tumor types over the past decade, but there remains a need for additional administration options to address treatment burden on patients and improve efficiencies in healthcare systems," said Gina Fusaro, Ph.D., vice president, global program lead, Bristol Myers Squibb. (businesswire.com)
Enadenotucirev is a virus that selectively replicates in tumor cells but not in normal cells. (bms.com)
Such viruses promote anti-tumor responses through a dual mechanism of action that is dependent on selective tumor cell killing and the induction of systemic anti-tumor immunity. (bms.com)
We are leading the integrated scientific understanding of both tumor cell and immune system pathways, through our extensive portfolio of investigational compounds and approved agents. (bms.com)
Agents in this class halt the cell cycle at the G1 phase in tumor cells. (medscape.com)
Various biological processes including immunoreaction of infection, tumor prevention, and human aging could cause telomere damage, tumor-related stress responses, and T regulatory (Treg) cells activation, which even trigger T cell senescence showing the distinctive phenotypic and functional alternation [ 9 , 10 ]. (hindawi.com)
Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. (pharmaceuticaldaily.com)
Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including the anti-tumor immune response. (pharmaceuticaldaily.com)
The resultant activation of T cells is then exploited for tumor elimination. (bdbiosciences.com)
Patient PBMCs are collected by leukapheresis followed by enrichment approaches to isolate T cells while removing other cells such as B cells, monocytes, neutrophils, dendritic cells and contaminating tumor cells. (bdbiosciences.com)
The fourth generation of CAR-T design attempts to deliver cytokines to modulate the tumor microenvironment either by activating host effector T cells or hampering host suppressors and reinforcing memory T cells. (bdbiosciences.com)
Circulating tumor DNA (ctDNA) is readily detectable in the plasma and cerebrospinal fluid of patients with central nervous system (CNS) lymphoma and is a strong prognostic biomarker for outcomes, a team of researchers from Germany and Stanford University reported at the 2021 American Society of. (ascopost.com)
A high tumor burden was present in 51% of patients, 35% had high-risk cytogenetics, and 39% had extramedullary disease. (cancertherapyadvisor.com)
Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY, Bristol-Myers Squibb Co.) and 2 cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. (blogspot.com)
for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. (blogspot.com)
Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY, Bristol-Myers Squibb Co.) as first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1(≥1%), as determined by an FDA-approved test, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. (blogspot.com)

PRINCETON, N.J.--( BUSINESS WIRE )-- Bristol-Myers Squibb Company (NYSE:BMY) today announced topline results from the Phase 3 CheckMate -331 study evaluating Opdivo (nivolumab) versus the current standard of care, topotecan or amrubicin (where approved), in patients with small cell lung cancer (SCLC) who relapsed following platinum-based chemotherapy. (bms.com)
CheckMate -331 is an open-label, randomized Phase 3 study evaluating Opdivo monotherapy versus chemotherapy in patients with relapsed small cell lung cancer (SCLC) following platinum-based chemotherapy. (bms.com)

CAR T-cell therapy that targets the CD19 antigen is now approved for relapsed and/or refractory B-cell lymphoma and B-cell acute lymphoblastic leukemia. (cancercenter.com)
The most active T cell endogenous inhibitory pathway is the immunoglobulin superfamily such as CD28/cytotoxic T lymphocyte antigen-4 (CTLA-4): B7-1/B7-2 receptor/ligand grouping, which plays a central role in coordinating immune responses [ 7 , 8 ]. (hindawi.com)
SummaryChimeric antigen receptor (CAR) T cells are genetically engineered cells containing fusion proteins combining an extracellular epitope-specific binding domain, a transmembrane and signaling domains of the T cell receptor. (deepdyve.com)

With the European Commission approval of this dual immunotherapy combination, patients and doctors will now have a new treatment option that has shown significant improvements in survival to manage this resistant disease. (pharmiweb.com)
We thank the patients and investigators involved in the CheckMate -743 trial, whose contributions were essential to bringing the first immunotherapy option to mesothelioma patients throughout the EU. (pharmiweb.com)
Systemic therapy is any treatment directed at destroying cancer cells throughout the body and may include chemotherapy, immunotherapy or newer precision cancer medicines. (hoapb.com)
Cancer cells are very good at finding ways to avoid immune destruction, however, so the goal of immunotherapy is to help the immune system eliminate cancer cells by either activating the immune system directly or inhibiting the mechanisms of suppression of the cancer. (hoapb.com)
Immunotherapy has transformed the treatment of advanced lung cancer, and thankfully, a diagnosis no longer means the same thing as it used to for many patients. (advfn.com)
The long-term efficacy seen with the dual immunotherapy regimen in CheckMate -227 reinforce the importance of nivolumab plus ipilimumab to transform outcomes for appropriate patients with metastatic non-small cell lung cancer. (advfn.com)
We are ecstatic to see Opdivo plus Yervoy continue to demonstrate almost double the overall survival rates as chemotherapy after six years of follow-up - the longest-ever for a Phase 3 trial with immunotherapy in metastatic non-small cell lung cancer. (advfn.com)
We thank the patients and investigators involved in the trial who have allowed us to advance our understanding of the importance of immunotherapy in treating patients' cancer in earlier stages. (santaclara.com)
The first-line treatment typically includes chemotherapy combined with immunotherapy, which is a combination of medications that destroy the cancer cells. (rarediseases.org)
Novel understanding in the interaction between immune system and cancer cells of the patient holds great promise for immunotherapy development [ 4 - 6 ]. (hindawi.com)

We aimed to identify the risk factors that predict transplantation outcomes in patients with MF who underwent matched or mismatched allo-SCT using a uniform myeloablative conditioning regimen consisting of busulfan and fludarabine with tacrolimus and methotrexate-based graft-versus-host disease prophylaxis. (bvsalud.org)
This treatment was complicated by graft-versus-host disease, and the patient required ongoing immunosuppression. (cdc.gov)

There is scarce data on MM patients with more than one high-risk cytogenetic aberration (ie, ultra- high-risk MM). This study was conducted to evaluate outcomes of newly diagnosed MM patients with ultra-high-risk MM who underwent autologous hematopoietic stem cell transplantation (autoHCT). (bvsalud.org)
The patient achieved a very good response to vincristine, doxorubicin (Adriamycin), and dexamethasone chemotherapy, and then he underwent autologous stem cell transplantation twice in 2007 and 2012. (jahjournal.org)

All it would take is a single example to prove him wrong, like-oh, you know-Lance Armstrong, the patients cared for by my pediatric oncology colleagues, or the patients I saw during my training cured of anal cancer by the Nigro protocol. (sciencebasedmedicine.org)
Dr Anna Sureda from the Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain discusses the standard of care for Hodgkin's Lymphoma and potential consolidation therapies. (thepatientschannel.com)
We are focused on researching innovative oncology therapies to improve outcomes for patients with lung cancer. (bms.com)
BEXXAR is currently being evaluated in a Phase III Southwest Oncology Group study evaluating CHOP (cyclophosphamide, hydroxydoxorubicin, vincristine (Oncovin), and prednisone) chemotherapy in combination with Rituximab versus CHOP in combination with BEXXAR in patients with newly-diagnosed follicular NHL. (salesandmarketingnetwork.com)
Bempegaldesleukin, Nektar's lead immuno-oncology candidate, is an investigational CD122-preferential IL-2 pathway agonist designed to provide activation and proliferation of cancer-killing immune cells, known as CD8+ effector T cells and natural killer (NK) cells. (nektar.com)
Through a unique multidisciplinary approach powered by translational science, we harness our deep scientific experience in oncology and Immuno-Oncology (I-O) research to identify novel treatments tailored to individual patient needs. (nektar.com)
In a single-institution retrospective review reported in JAMA Oncology, Zurko et al found that early intrathecal therapy with hydrocortisone with or without intrathecal chemotherapy was effective in treating grade ≥ 3 immune effector cell-associated neurotoxicity syndrome (ICANS) in patients. (ascopost.com)
Food and Drug Administration granted accelerated approval to rucaparib (RUBRACA, Clovis Oncology, Inc.) for patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. (blogspot.com)

The low genetic barrier to oseltamivir means that resistance is a likely consequence of monotherapy in immunocompromised patients. (cdc.gov)
Dual targeting BTK and BCL2 with ibrutinib and venetoclax has increased complete response rate compared with ibrutinib monotherapy in MCL patients but it is unlikely that this combination therapy will lead to a long term cure of the disease [ 3 ]. (bmj.com)
The safety profile of Opdivo in this trial was consistent with that observed in previously reported monotherapy studies involving patients with SCLC. (bms.com)
As part of this program, the Company is investigating the role of Opdivo plus Yervoy and Opdivo monotherapy versus placebo in the frontline setting as a maintenance therapy for patients with SCLC who do not progress on first-line chemotherapy. (bms.com)
On March 25, 2011, the U.S. Food and Drug Administration (FDA) approved Yervoy 3 mg/kg monotherapy for patients with unresectable or metastatic melanoma. (pharmaceuticaldaily.com)

Hematopoietic cell transplantation has become a cornerstone in the management of patients with lymphoma. (bloodline.net)

Evaluating the effectiveness and safety of sacituzumab govitecan versus chemotherapy in patients with HR+, HER2- metastatic breast cancer. (medivizor.com)

Familial aggregation of Hodgkin lymphoma and related tumors. (medscape.com)
Загальні відомості про лімфоми Lymphomas are a heterogeneous group of tumors arising in the reticuloendothelial and lymphatic systems. (msdmanuals.com)
The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. (lookformedical.com)
Food and Drug Administration granted accelerated approval to capmatinib (TABRECTA, Novartis) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. (blogspot.com)

The various types have little similarity to each other, and are categorized by the World Health Organization according to cell origin (B cell, T cell/NK cell). (oncolink.org)

At a median follow-up of 35.6 months, the 3-year cumulative incidence of relapse (CIR), nonrelapse mortality (NRM), and overall survival (OS) for all study patients were 27%, 20%, and 65%, respectively. (bvsalud.org)
In a homogenous cohort of MF patients uniformly treated with busulfan/fludarabine myeloablative conditioning and methotrexate-based GVHD prophylaxis, we show that donor choice and HCT-CI are the 2 strongest predictors for improved survival after allo-SCT. (bvsalud.org)
Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. (medscape.com)
Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
The trial met its primary endpoint, showing superior overall survival (OS) with Opdivo plus Yervoy versus chemotherapy (pemetrexed and cisplatin or carboplatin) in all randomized patients. (pharmiweb.com)
For many years palliation of symptoms with alkylating agents or hydroxyurea was the only therapy available and this had little or no effect on the survival of patients with MF. (bloodline.net)
Bristol Myers Squibb (NYSE: BMY) today announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of patients with metastatic non-small cell lung cancer (mNSCLC), regardless of PD-L1 expression levels. (advfn.com)
The study did not meet its primary endpoint of overall survival (OS) with Opdivo versus chemotherapy. (bms.com)
From the time of diagnosis, the median range of survival for extensive-stage SCLC (ES-SCLC) patients is between eight and 13 months. (bms.com)
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -77T trial met its primary endpoint of improved event-free survival (EFS) as assessed by Blinded Independent Central Review (BICR) in patients with resectable stage IIA to IIIB non-small cell lung cancer (NSCLC). (santaclara.com)
The data showed that SG significantly improved survival without cancer progression compared to chemotherapy in these. (medivizor.com)
The focus of our research is to increase quality, long-term survival for patients and make cure a possibility. (nektar.com)
Chemotherapy contributes only just over 2% to the five year survival rate and any contribution from radiotherapy can just as easily be explained by other scientific rationales. (respectfulinsolence.com)
Also, it uses 5 year survival exclusively, completely neglecting that chemotherapy can prevent late relapses, and there were also a lot of inconsistencies and omissions in that leukemias were not included, while leukemia is one type of cancer against which chemotherapy is most efficacious. (respectfulinsolence.com)
Outcomes of patients with triple-exposed RRMM is poor, with infrequent deep and durable responses and a median survival of 3 to 4 months," said Nikhil C. Munshi, MD, of the Dana-Farber Cancer Institute in New York City, who was lead author and presenter of the study. (cancertherapyadvisor.com)

CheckMate -67T is a Phase 3 randomized, open-label trial evaluating subcutaneous administration of Opdivo co-formulated with Halozyme's proprietary recombinant human hyaluronidase, rHuPH20, or subcutaneous nivolumab (nivolumab and hyaluronidase) compared to intravenous (IV) Opdivo , in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior systemic therapy. (businesswire.com)
This trial presents an opportunity to potentially bring a subcutaneous formulation of Opdivo to patients. (businesswire.com)
A total of 495 patients were randomized to either subcutaneous nivolumab or IV Opdivo . (businesswire.com)
ORR was similar across the Opdivo plus Yervoy and chemotherapy arms at 40% (95% CI: 34.1 to 45.4) and 43% (95% CI: 37.1 to 48.5), respectively. (pharmiweb.com)
Of the patients who responded to Opdivo plus Yervoy , 32% had ongoing responses at two years (vs. 8% of chemotherapy responders). (pharmiweb.com)
We are excited to partner with PsiOxus to evaluate the combination of Opdivo and enadenotucirev to accelerate our understanding of its potential as a new therapeutic option for cancer patients. (bms.com)
They are our ideal partner since we share a common vision of exploring novel combinations such as enadenotucirev and Opdivo to expand the range of patients who potentially respond favorably to checkpoint inhibitor therapy. (bms.com)
In a prespecified interim analysis, the perioperative regimen of neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo showed a statistically significant and clinically meaningful improvement in EFS compared to neoadjuvant chemotherapy and placebo followed by surgery and adjuvant placebo. (santaclara.com)
CheckMate -77T is a Phase 3 randomized, double-blind, placebo-controlled, multi-center trial evaluating neoadjuvant Opdivo with chemotherapy followed by surgery and adjuvant Opdivo versus neoadjuvant chemotherapy and placebo followed by surgery and adjuvant placebo in 452 patients with resectable stage IIA to IIIB non-small cell lung cancer (NSCLC). (santaclara.com)
SAN FRANCISCO , Aug. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration ( FDA ) has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin (NKTR-214) in combination with Bristol-Myers Squibb's Opdivo ® (nivolumab) for the treatment of patients with previously untreated unresectable or metastatic melanoma. (nektar.com)
The Opdivo trials have contributed to gaining a deeper understanding of the potential role of biomarkers in patient care, particularly regarding how patients may benefit from Opdivo across the continuum of PD-L1 expression. (pharmaceuticaldaily.com)
CheckMate -914 is a Phase 3, randomized, double-blind, placebo-controlled trial evaluating Opdivo in combination with Yervoy compared to placebo (Part A), and Opdivo alone compared to placebo (Part B), in patients with localized renal cell carcinoma (RCC) who have undergone surgery to remove part or all of a kidney and who are at moderate to high risk of relapse. (wapakdailynews.com)

Fifty-six patients (71%) received post-transplantation maintenance therapy. (bvsalud.org)
Thirty-six patients (46%) achieved MRD-negative ≥VGPR at day +100 after autoHCT, and 40 patients (51%) did so at best post-transplantation response. (bvsalud.org)

When a patient presents with neck lymphadenopathy and risk factors for a head and neck cancer, a fine-needle aspiration is usually advised as the initial diagnostic step, followed by excisional biopsy if squamous cell histology is excluded. (medscape.com)
We conducted a retrospective single-center chart review analysis of adult patients with ultra-high-risk MM who underwent autoHCT between 2008 and 2018 at MD Anderson Cancer Center. (bvsalud.org)
Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, accounting for more than 431,000 new cases and 179,000 deaths worldwide each year. (businesswire.com)
The goal of the company's cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. (businesswire.com)
A favorite claim made by cancer quacks (and quacks of all varieties, actually) is that chemotherapy doesn't work. (sciencebasedmedicine.org)
Note how Adams portrays screening for cancer and chemotherapy as a deadly scam designed solely to enrich the "cancer industry" as it kills patients. (sciencebasedmedicine.org)
There is not a single cancer patient that has ever been cured by chemotherapy. (sciencebasedmedicine.org)
When I first encountered that cartoon a few years ago, I was a bit surprised that even Mike Adams would go so far as to make such an absolutist statement that not a single person has ever been cured of cancer by chemotherapy in the entire history of "western medicine. (sciencebasedmedicine.org)
From a cancer patient population and public health perspective, cancer chemotherapy (chemo) has been a major medical advance . (sciencebasedmedicine.org)
Mesothelioma can be a devastating diagnosis for patients and their families, and the disease has a significant impact throughout Europe, which has the highest incidence rate of mesothelioma globally," said Stefania Vallone, board member, Women Against Lung Cancer in Europe. (pharmiweb.com)
Mesothelioma is often detected decades after exposure to asbestos, and for years these patients have faced this aggressive cancer with few treatment options. (pharmiweb.com)
Shanbhag, S & Ambinder, RF 2018, ' Hodgkin lymphoma: A review and update on recent progress ', CA Cancer Journal for Clinicians , vol. 68, no. 2, pp. 116-132. (johnshopkins.edu)
And, if CAR T-cell therapy fails, standardized treatment protocols have yet to be determined to stop the cancer from growing, though some treatments have shown limited success. (cancercenter.com)
But, as with many cancer therapies, CAR T doesn't always eradicate the disease and it may still progress in a significant number of patients following treatment. (cancercenter.com)
T-cells have receptors that can latch onto the antigens (proteins) on the surface of cancer cells, but a patient's T-cells do not have the specific receptor needed to successfully identify and fight his or her cancer. (cancercenter.com)
Technicians send the removed T-cells to a laboratory, where they are modified into CAR T-cells that are better equipped to fight the patient's cancer. (cancercenter.com)
The lab re-engineers the T-cells by inserting genetic information that directs the T-cells to make receptors for the specific type of cancer cells in the patient. (cancercenter.com)
The modified cells, now designed to better identify and kill the patient's cancer cells, then need to be multiplied before being infused into the patient's body. (cancercenter.com)
Chemotherapy is any treatment involving the use of drugs to kill cancer cells. (hoapb.com)
Cancer chemotherapy may consist of single drugs or combinations of drugs, administered through a vein, or delivered orally in the form of a pill. (hoapb.com)
Most chemotherapy drugs cannot tell the difference between a cancer cell and a healthy cell. (hoapb.com)
Once a genetic abnormality is identified, a specific targeted therapy can be designed to attack a specific mutation or other cancer-related change in the DNA programming of the cancer cells. (hoapb.com)
Adcetris is a precision cancer medicine that targets the CD30 protein present on HL cells. (hoapb.com)
The immune system is a network of cells, tissues, and biologic substances that defend the body against viruses, bacteria, and cancer. (hoapb.com)
The immune system recognizes cancer cells as foreign and can eliminate them or keep them in check-up to a point. (hoapb.com)
One type creates a new, individualized treatment for each patient by removing some of the person's immune cells, altering them genetically to kill cancer, and then infusing them back into the bloodstream the other uses precision medications to enhance the immune systems response to the cancer. (hoapb.com)
PD-1 and PD-L1 are proteins that inhibit certain types of immune responses, allowing cancer cells to evade detection and attack by certain immune cells in the body. (hoapb.com)
It has long been known that oxidative stress is an essential mechanism by which chemotherapy works to treat cancer. (pinestreetfoundation.org)
Taking a deeper look into the research literature yields many examples where oxidative stress on cancer cells has been shown to be counterproductive. (pinestreetfoundation.org)
For example, a study using human Burkitt lymphoma cells found that oxidative stress actually interferes with the ability of the chemotherapy drugs doxorubicin, cisplatin, etoposide, and cytarabine to cause cancer cell death. (pinestreetfoundation.org)
When oxidative stress levels are reduced in cancer cells, their growth is more easily controlled through a process called apoptosis. (pinestreetfoundation.org)
However, when oxidative stress levels go up, cancer cell death happens through a slower, messier, and less effective pathway called pyknosis or necrosis. (pinestreetfoundation.org)
Additionally, the ability of the body to "clean up" the resulting cellular debris from cancer cell death is also inhibited by oxidative stress. (pinestreetfoundation.org)
Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer, representing up to 84% of diagnoses. (santaclara.com)
SG) compared to chemotherapy in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC). (medivizor.com)
In a nutshell This study evaluated the effectiveness and safety of the combination of trifluridine-tipiracil (Lonsurf) and bevacizumab (Avastin) in patients with unresponsive (refractory) metastatic colorectal cancer (mCRC) in a real-world setting. (medivizor.com)
Evaluating the effectiveness of abemaciclib alone or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer resistant to hormone therapy. (medivizor.com)
In a nutshell This study evaluated the effectiveness of abemaciclib (Verzenio) alone or in combination with tamoxifen (Nolvadex) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC) resistant to hormone therapy. (medivizor.com)
A CAR-T therapy is a type of treatment in which a patient's T cells are changed in the laboratory so they will attack cancer cells. (survivornet.com)
Cancer Stat Facts: Non-Hodgkin Lymphoma. (medscape.com)
Bempegaldesleukin is designed to stimulate cancer-killing immune cells in the body by targeting CD122 receptors found on the surface of these immune cells. (nektar.com)
We look forward to expanding the registrational program currently underway for bempeg and are committed to the development of potential new combination therapies to address the unmet needs of patients living with cancer. (pharmaceuticaldaily.com)
Nonetheless, we are dedicated to continuing research and advancing cancer care for all patients with RCC. (wapakdailynews.com)
Almost every year new genes were detected being targetable, and drugs have been developed and provided for those patients being diagnosed with such a lung cancer. (deepdyve.com)
It was a brilliant bit of parody of "Secret"-like thinking, in essence taking the denial of a cancer patient and juxtaposing it in an overblown manner with his obviously ill appearance. (respectfulinsolence.com)
O'Brien C, Fogarty E, Walsh C, Dempsey O, Barry M, Kennedy MJ, McCullagh L, , The cost of the inpatient management of febile neutropenia in cancer patients - a micro-costing study in the Irish healthcare setting. (tcd.ie)
Specialists from Penn Medicine's Abramson Cancer Center discuss management of low risk thyroid cancer patients. (pennmedicine.org)
Read more of Cancer Therapy Advisor 's coverage of the ASCO 2021 meeting by visiting the conference page . (cancertherapyadvisor.com)
Food and Drug Administration approved brigatinib (ALUNBRIG, ARIAD Pharmaceuticals Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (blogspot.com)
Food and Drug Administration approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals, LP) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (blogspot.com)
Adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). (blogspot.com)
Download or order The Leukemia & Lymphoma Society's free fact sheet, Choosing a Blood Cancer Specialist or Treatment Center . (schoolandyouth.org)
The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against cancer. (schoolandyouth.org)
LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care. (schoolandyouth.org)

ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of cHL that is expressed on the surface of several types of lymphomas. (businesswire.com)

White blood cells formed in the body's lymphoid tissue. (lookformedical.com)

REAL/WHO- [6] - classification includes leukemias and lymphomas, with 3 categories based on lineage and morphology (Hodgkin, B cell, and T/NK cell). (oncolink.org)

ICE in the context of chemotherapy is an acronym for one of the chemotherapy regimens, used in salvage treatment of relapsed or refractory non-Hodgkin's lymphoma and Hodgkin lymphoma. (wikipedia.org)
Thomas RK, Re D, Wolf J, Diehl V. Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed-Sternberg cells. (medscape.com)
Re D, Kuppers R, Diehl V. Molecular pathogenesis of Hodgkin's lymphoma. (medscape.com)
Characteristics of Hodgkin's lymphoma after infectious mononucleosis. (medscape.com)
A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). (medscape.com)
High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
GSK News) announced today long-term efficacy data from a Phase II trial of a single one-week course of frontline treatment with the BEXXAR Therapeutic Regimen (Tositumomab and Iodine I-131 Tositumomab) in 76 patients with newly diagnosed advanced follicular non-Hodgkin's lymphoma (NHL). (salesandmarketingnetwork.com)
Martí-Carvajal AJ, Cardona AF, Lawrence A. Interventions for previously untreated patients with AIDS-associated non-Hodgkin's lymphoma. (medscape.com)
Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. (medscape.com)
The purpose of this trial is to develop an alternative treatment for patients with poor risk non-Hodgkin's lymphoma. (stanford.edu)

Treatment of patients with stage II, III, IV or recurrent Hodgkin lymphoma typically consists of systemic therapy. (hoapb.com)

Randomized phase II trial on primary chemotherapy with high-dose methotrexate and high-dose cytarabine with or without thiotepa, and with or without rituximab, followed by brain irradiation vs. high-dose chemotherapy supported by autologous stem cells transplantation for immunocompetent patients with newly diagnosed primary cns lymphoma. (clinicaltrialsregister.eu)

Bone marrow involvement is more common in elderly patients and those with advanced-stage disease, systemic symptoms, or a high-risk histology. (medscape.com)
Prior to autoHCT, 52 patients (66%) achieved a very good partial response or better (≥VGPR), whereas 23 patients (29%) achieved minimal residual disease (MRD)-negative ≥VGPR. (bvsalud.org)
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. (medscape.com)
HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease. (medscape.com)
CAR T doesn't always eradicate the disease and it may still progress in a significant number of patients following treatment. (cancercenter.com)
That left a substantial minority of patients in the study still experiencing disease progression following therapy, and 38 percent of the study group died within a median follow-up period of 14.5 months (ranging from 0.4 months to three years). (cancercenter.com)
These medicines are currently used mainly in the treatment of advanced disease alone or in combination with other therapies. (hoapb.com)
Despite responding to initial treatment, the majority of patients experience relapse within one year (the return of disease after a period of improvement). (bms.com)
While many non-metastatic NSCLC patients are cured by surgery, 30% to 55% develop recurrence and die of their disease despite resection, contributing to a need for treatment options administered before surgery (neoadjuvant) and/or after surgery (adjuvant) to improve long-term outcomes. (santaclara.com)
Additionally, 50% of patients survived without progression of disease at 8 years following therapy. (salesandmarketingnetwork.com)
The management selected will be based on a number of patient and disease characteristics. (rarediseases.org)
Risk of lymphoproliferative malignancy in relation to small intestinal histopathology among patients with celiac disease. (medscape.com)
Hodgkin disease. (lookformedical.com)
Large cells, usually multinucleate, whose presence is a common histologic characteristic of classical HODGKIN DISEASE. (lookformedical.com)
The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA. (lookformedical.com)
Identification of patients at risk of central nervous system disease is critical to accurately identify candidates for central nervous system prophylaxis vs. therapy. (haematologica.org)
Patients must have an EKG within 42 days prior to registration that shows no significant abnormalities that are suggestive of active cardiac disease. (stanford.edu)
Experts from Penn Medicine's Endocrine Disease team discuss the management of Thyroid Nodules and address critical decision making points along this patient-centered pathway of treatment. (pennmedicine.org)
The patient had disease progression in September 2015 and was started on carfilzomib. (jahjournal.org)
The patient started on pomalidomide in November 2015 and showed less than a partial response but no disease progression. (jahjournal.org)
The majority of patients (88%) had received bridging therapy, "suggesting an aggressive nature of the disease for the patients who were entered in the study," Dr Munshi noted. (cancertherapyadvisor.com)
Overall, 39% of patients with at least a VGPR were negative for minimal residual disease, as well as 26% of patients who achieved at least a CR. (cancertherapyadvisor.com)
After PET-positive disease was reconfirmed, patients received a lymphodepletion regimen comprised of fludarabine at 30 mg/m2 and cytarabine at a dose of 300 mg/m2 for 3 days. (onclive.com)
The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. (schoolandyouth.org)

The programmed death-1 inhibitors nivolumab and pembrolizumab have both demonstrated high response rates and durable remissions in patients with relapsed/refractory HL. (johnshopkins.edu)
In collaboration with our partner Bristol-Myers Squibb , we plan to work closely with FDA as we continue to advance our development program of bempegaldesleukin in combination with nivolumab in advanced melanoma patients," said Dr. Stephen Doberstein, SVP, Research and Development and Chief R&D Officer of Nektar Therapeutics . (nektar.com)

A CAR T-cell study out of Massachusetts General Hospital , reported in Blood Advances in July, looked at 100 patients who received some form of CAR T-cell therapy for lymphoma, myeloma or B-cell acute lymphoblastic leukemia. (cancercenter.com)
Evaluating combined treatment of venetoclax and gilteritinib for relapsed or refractory acute myeloid leukemia with the FLT3 mutation. (medivizor.com)
In a nutshell This study evaluated the tolerability and effectiveness of combined therapy using venetoclax (Venclexta) and gilteritinib (Xospata) in patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) with the FLT3 (FMS-related tyrosine kinase 3) mutation. (medivizor.com)
Misdiagnosis of acute hepatitis E virus (HEV) infection as drug-induced liver injury (DILI) may lead to discontinuation of effective chemotherapy. (journaltocs.ac.uk)

Several factors are known to predict transplantation outcomes. (bvsalud.org)
However, most studies lack homogeneity in conditioning regimens used, limiting their ability to assess prognostic factors on transplantation outcomes. (bvsalud.org)
Dual targeting BTK and BCL2 with ibrutinib and venetoclax has improved outcomes in MCL patients who were predicted not to respond to conventional therapy, but it is unlikely to be curative. (bmj.com)
Much of the current confusion and controversy in MDS treatment stems from the lack of consensus on which therapies to use in which patients, and what realistic outcomes might be. (bloodline.net)

See also Hodgkin Lymphoma Treatment Protocols . (medscape.com)

This positive CHMP opinion is an important milestone that recognizes [liso-cel] as a differentiated cell therapy with the potential to address unmet needs for patients in the European Union with aggressive lymphomas who have limited treatment options," Anne Kerber, senior vice president of Cellular Therapy Development at Bristol Myers Squibb, stated in a press release. (onclive.com)

That doesn't even count all the patients with leukemia or lymphoma cured primarily by chemotherapy. (sciencebasedmedicine.org)
Evaluating the effectiveness and safety of asciminib in real-world patients with chronic myeloid leukemia previously treated with ponatinib. (medivizor.com)
Of note, these results were achieved with BEXXAR given as a single treatment, completed within one week, which made it a convenient regimen for these patients," said Mark Kaminski, Professor of Internal Medicine and Director, Leukemia/Lymphoma Program at the University of Michigan and lead investigator of this study. (salesandmarketingnetwork.com)
Atypical morphologic features have been reported more commonly in plasma cell leukemia. (jahjournal.org)
The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. (schoolandyouth.org)

2000) A second study, involving the chemotherapy drugs etoposide and calcimycin, confirms this finding: Human Burkitt's lymphoma cells were unable to die quickly by apoptosis in the presence of oxidative stress and instead died using the slower and messier method of necrosis. (pinestreetfoundation.org)
Patients with known allergy to etoposide or a history of Grade 3 hemorrhagic cystitis with cyclophosphamide are not eligible. (stanford.edu)

We detail the development of oseltamivir-resistant pandemic (H1N1) 2009 in a chronically immunocompromised patient and the pitfalls encountered when treating such patients with neuraminidase inhibitors. (cdc.gov)
Our patient demonstrated that a single PCR-negative test does not reliably determine the end of viral shedding, which continued despite co-treatment with 2 neuraminidase inhibitors. (cdc.gov)
Neuraminidase inhibitors interfere with the release of progeny influenza virus from their infected host cells. (cdc.gov)
Which medications in the drug class Antineoplastic Agents, mTOR Kinase Inhibitors are used in the treatment of Non-Hodgkin Lymphoma (NHL)? (medscape.com)
To the Editor: We detail the development of oseltamivir-resistant pandemic (H1N1) 2009 in a chronically immunocompromised patient and the pitfalls encountered when treating such patients with neuraminidase inhibitors. (blogspot.com)

In this analysis, BEXXAR was shown to have a favorable cost-effectiveness profile compared to alternative treatments, including chemotherapy, ZEVALIN (Ibritumomab Tiuxetan), and maintenance Rituximab. (salesandmarketingnetwork.com)
Several studies 10 7 5 4 and a recent meta-analysis 1 have described a decrease in rates of CNS relapse in the post-rituximab era (probably due to improved control of systemic lymphoma), in addition to a change in the pattern of CNS relapse, with predominance of parenchymal over leptomeningeal relapse, isolated over combined (systemic plus CNS) relapses, and delayed CNS relapses. (haematologica.org)
Similarly, recently published British guidelines 11 have concluded that the incidence of CNS relapse decreased after the introduction of rituximab ( Table 1 ). (haematologica.org)

Conclusions This case suggests that haplo-CAR T cell therapy can be effective in controlling lymphoma that failed to respond to autologous CAR T cell therapy and overcome limitation of autologous CAR T cells, thus may be one possible regimen before the era of off-the-shelf "universal" CAR T cell therapy. (bmj.com)
Although the same doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapeutic regimen has been the mainstay of therapy over the last 30 years, risk-adapted approaches have helped de-escalate therapy in low-risk patients while intensifying treatment for higher risk patients. (johnshopkins.edu)
The patient typically undergoes a lymphocyte-depleting regimen of chemotherapy prior to the infusion of the CAR T-cells. (cancercenter.com)
This pivotal phase 2 KarMMa trial treated 128 patients with MM - who had received 3 or more prior regimens, including an immunomodulatory drug, proteosome inhibitor, and an anti-CD38 antibody and who were refractory to their last regimen - with ide-cel at 150 to 450 × 10 6 CAR T cells. (cancertherapyadvisor.com)

The belief that T-cell lymphomas have a worse prognosis than B-cell lymphomas remains controversial. (oncolink.org)
Background The aggressive form of Mantle cell non-hodgkin B cell lymphoma (MCL) has a dismal prognosis. (bmj.com)
MCL can be both indolent or aggressive, in either case it responds poorly to chemotherapy and consequently the aggressive form has a dismal prognosis assessed by incorporating Ki-67 proliferation index and Mantle Cell International Prognostic Index scores. (bmj.com)
however, patients who experience early relapse, or who are refractory to initial immunochemotherapy have a poor prognosis ( 3 ). (frontiersin.org)

Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC. (medivizor.com)
A 78-year-old woman with lung adenocarcinoma and multiple bone metastases received maintenance therapy with pemetrexed + pembrolizumab for a year. (journaltocs.ac.uk)

Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines. (stanford.edu)

A histologic diagnosis of Hodgkin lymphoma is always required. (medscape.com)
[ 6 ] provide consensus opinions from leading experts on evidence-based approaches to the diagnosis and treatment of Hodgkin lymphoma. (medscape.com)
Fine-needle aspirate is sufficient for lymphoma diagnosis but rarely adequate for subtyping, thus excisional or incisional biopsy is considered mandatory[5]. (oncolink.org)

Anatomy23

Organisms5

Diseases55

Chemicals and Drugs53

Analytical, Diagnostic and Therapeutic Techniques and Equipment88

Psychiatry and Psychology1

Phenomena and Processes25

Disciplines and Occupations2

Anthropology, Education, Sociology and Social Phenomena2

Humanities1

Information Science5

Named Groups5

Health Care26

Geographicals1

Multiple myeloma13

DLBCL22

Mantle Cell Lym6

Large B‑cell l7

Classical Hodgkin6

Diffuse2

ASCT5

Allogeneic7

Malignancies15

Blood and marrow transplantation2

High-dose chemotherapy with autologous2

Clinical29

Remission8

Transplant9

Peripheral T-cell lym1

Follicular lymphoma3

Malignant11

Combination with chemotherapy2

Bone marrow transpla4

Brentuximab vedotin1

Cancers15

Nodular3

Conventional chemotherapy1

Chimeric antigen receptor3

Radiation19

Tumor16

Platinum-based chemotherapy2

Antigen3

Immunotherapy10

Graft-versus-2

Underwent autologous2

Oncology8

Monotherapy5

Hematopoietic Cell Transplantation1

Versus chemotherapy in patients1

Tumors4

World Health Organ1

Survival15

Opdivo12

Post-transplantation2

Cancer54

Antibody-drug conjugate1

Lymphoid1

Leukemias and lymphomas1

Hodgkin's Lymphoma10

Systemic therapy1

Newly diagnosed1

Disease24

Nivolumab2

Acute4

Outcomes4

Treatment Protocols1

Aggressive lymphomas1

Leukemia5

Etoposide2

Inhibitors5

Rituximab3

Regimen4

Prognosis4

Pembrolizumab2

Investigational1

Diagnosis3